Skip to content

Nora Satybaldiyeva

School of Public Health, Department of Medicine, University of California San Diego Herbert Wertheim, San Diego, CA, USA.

4 papers in the library · 30 citations · publishing 2024-2026

Papers

State Cannabis and Psychedelic Legislation and Microdosing Interest in the US.

JAMA health forum June 7, 2024 Kevin H Yang, Nora Satybaldiyeva, Matthew R Allen et al. 16 citations

Public interest in psychedelic microdosing in the US surged 13.4-fold from 2015 to 2023, reaching 3.0 million Google searches in 2023. State-level cannabis and psychedelic legislative reforms were associated with increased search rates: local psychedelic decriminalization with an increase of 22.4 per 10 million searches, statewide psychedelic therapeutic legalization and decriminalization with 28.9 per 10 million, recreational cannabis laws with 40.9 per 10 million, and medical cannabis laws with 11.5 per 10 million. From August to December 2023, 27% of the variation in monthly search rates between states was explained by differences in cannabis and psychedelics legal status.

DOI: 10.1001/jamahealthforum.2024.1653 Full text

Need for a Public Health Response to the Unregulated Sales of Amanita muscaria Mushrooms

American Journal of Preventive Medicine June 10, 2024 Eric C. Leas, Nora Satybaldiyeva, Wayne Kepner et al. 10 citations

Use of psilocybin-containing mushrooms among U.S. adults rose from 11.4% in 2021 to 12.3% in 2022, making them the most commonly used hallucinogenic substance. This growing interest has spurred a commercial market for other mushrooms, including Amanita muscaria, which contains the psychoactive compounds muscimol and ibotenic acid.

DOI: 10.1016/j.amepre.2024.05.006 Amanita Public health Business Environmental health +4

Prevalence and Correlates of Lifetime Ecstasy/MDMA Use Among Asian American and Pacific Islander Adult Populations in the United States, 2015–2020

Journal of Psychoactive Drugs March 3, 2025 Wayne Kepner, Patricia Dionicio, Katie Bailey et al. 3 citations

About 1 in 20 Asian American and Pacific Islander adults (5.1%) have used ecstasy/MDMA in their lifetime, based on a nationally representative sample from 2015-2020. Females had higher odds of use than males, and adults aged 26-34 had higher odds than those aged 18-25, while those aged 50 or older had lower odds. Lifetime use of other substances—cannabis, ketamine, LSD, cocaine, psilocybin, prescription opioids, and prescription stimulants—was associated with increased odds of ecstasy/MDMA use. Variations by age, sex, family income, substance type, and mental health service use point to the need for targeted public health strategies.

DOI: 10.1080/02791072.2025.2474243 MDMA Ecstasy Pacific islanders Demography +6